Effector Therapeutics Inc

Market Cap

$3K

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.00+$0.00 (+0.00%)

Jun 22, 2026

52W High $0.0052W Low $0.00

Company Details

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, ...

Leadership

Davide Ruggero Ph.D.Founder

Co-Founder and Member of Clinical & Scientific Advisory Board

Kevan M. Shokat Ph.D.Founder

Co-Founder and Member of Clinical & Scientific Advisory Board

IPO Date

Aug 26, 2021

Website

effector.com

Key Metrics TTM

Revenue

$162.0K

-95.4% YoY

Net Income

-$35M

EPS (Diluted)

Free Cash Flow

-$29M

Revenue / Share

$0.06

Gross Margin

31.5%

Operating Margin

-20463.6%

Net Margin

-21376.5%

FCF Margin

-18071.0%

P/S

0.0x

P/E

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue by Product

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee